|
Results of the evaluation of PSA values have been reported in the clinical phase
1 study that SpectraCure is currently running for treatment of patients with
recurrent prostate cancer, using the company''s photodynamic therapy (PDT)
method. PSA (prostate-specific antigen) is a blood marker that can indicate the
presence of a tumour in the prostate.
The most recently treated patients had PSA values of 4.7 ng/ml and 5.7 ng/ml,
respectively, prior to treatment. One month after treatment, the values had
decreased to 0.3 ng/ml and 3.5 ng/ml, respectively.
SpectraCure has previously reported that MR images of the prostate taken one
week after treatment showed a clear destruction of the tumour area, which is the
intended effect of the PDT treatment.
It should be emphasized that the main objective of the Phase 1 study is to show
that SpectraCure''s treatment method is safe, and to determine the correct dose
level. The preliminary results also suggest that the method has the intended
effect, which is a secondary objective for the phase 1 study.
For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46-(8)
-503 000 50.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments
for medical laser applications and physics. The company focuses on cancer
treatments using medical systems with laser light sources and reactive drugs,
which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment
methodology suitable for internal solid tumours of various kind, e.g. prostate
and abdominal salivary glands, but also other indications such as cancer tumours
in the head and neck region |